![David S. McCullough](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David S. McCullough
Chief Executive Officer at
Enterin, Inc.
Profile
David S.
McCullough is currently the Chief Executive Officer & Director at Enterin, Inc. Prior to his current position, he held the role of Director-Global Corporate Development at Merck KGaA from 2002 to 2007.
Following that, he served as the VP-Strategic Planning & Commercialization at BioCryst Pharmaceuticals, Inc. from 2007 to 2012.
Mr. McCullough completed his undergraduate degree at Western Illinois University.
David S. McCullough active positions
| Companies | Position | Start |
|---|---|---|
Enterin, Inc.
 Enterin, Inc. BiotechnologyHealth Technology Develops novel compounds that dysfunctional gut-brain axis in patients with neurodegenerative disease | Chief Executive Officer | 16/10/2020 |
Former positions of David S. McCullough
| Companies | Position | End |
|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Corporate Officer/Principal | 12/12/2012 |
| MERCK KGAA | Corporate Officer/Principal | 01/04/2007 |
Training of David S. McCullough
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
67
1st degree connections
4
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
BioCryst Pharmaceuticals, Inc.
 BioCryst Pharmaceuticals, Inc. BiotechnologyHealth Technology Designs and develops oral small-molecule & injectable protein therapeutics | Health Technology |
Merck KGaA
 Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
Western Illinois University
 Western Illinois University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enterin, Inc.
Enterin, Inc. BiotechnologyHealth Technology Develops novel compounds that dysfunctional gut-brain axis in patients with neurodegenerative disease | Health Technology |
- Stock Market
- Insiders
- David S. McCullough
